middle.news
Actinogen’s XanaMIA Trial Clears Key Hurdle with Positive Interim Review
10:02am on Friday 30th of January, 2026 AEDT
•
Biotechnology
Read Story
Actinogen’s XanaMIA Trial Clears Key Hurdle with Positive Interim Review
10:02am on Friday 30th of January, 2026 AEDT
Key Points
Independent Data Monitoring Committee recommends continuation of XanaMIA trial
Interim analysis covers 37% of final dataset with positive safety and efficacy signals
Final topline results expected November 2026 after full enrolment of 247 participants
Open-label extension phase to begin March 2026 offering active treatment to participants
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE